Literature DB >> 7692443

Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.

F J Burrows1, P E Thorpe.   

Abstract

Antibody-based therapy of solid tumors has met with limited success, chiefly because solid tumors are relatively impermeable to macromolecules. This problem could be circumvented by attacking the readily accessible endothelial cells of the tumor vascular bed. We have developed a model to test this "vascular targeting" approach in which cytokine gene transfection of the tumor cells causes them to induce an experimental marker selectively on tumor vascular endothelium. An anti-tumor endothelial cell immunotoxin caused complete occlusion of the tumor vasculature and dramatic regressions of large solid tumors. By contrast, a conventional anti-tumor cell immunotoxin of equivalent in vitro potency produced only minor, transient antitumor effects but, when combined, the two immunotoxins induced permanent complete remissions in over half of the animals. These experiments indicate that immunotoxins directed against recently described markers on vascular endothelial cells in human tumors could provide a general treatment for solid tumors in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692443      PMCID: PMC47488          DOI: 10.1073/pnas.90.19.8996

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  A survey of transplantable and transmissible animal tumors.

Authors:  L J DUNHAM; H L STEWART
Journal:  J Natl Cancer Inst       Date:  1953-04       Impact factor: 13.506

2.  Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B.

Authors:  P P Knowles; P E Thorpe
Journal:  Anal Biochem       Date:  1987-02-01       Impact factor: 3.365

3.  Purification of ricin A1, A2, and B chains and characterization of their toxicity.

Authors:  R J Fulton; D C Blakey; P P Knowles; J W Uhr; P E Thorpe; E S Vitetta
Journal:  J Biol Chem       Date:  1986-04-25       Impact factor: 5.157

4.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

5.  Variable expression of Ia antigens on the vascular endothelium of mouse skin allografts.

Authors:  R M de Waal; M J Bogman; C N Maass; L M Cornelissen; W J Tax; R A Koene
Journal:  Nature       Date:  1983 Jun 2-8       Impact factor: 49.962

Review 6.  Tumor angiogenesis.

Authors:  J Folkman
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

7.  Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms.

Authors:  A A Epenetos; D Snook; H Durbin; P M Johnson; J Taylor-Papadimitriou
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

8.  A shared alloantigenic determinant on Ia antigens encoded by the I-A and I-E subregions: evidence for I region gene duplication.

Authors:  A Bhattacharya; M E Dorf; T A Springer
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

9.  Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain.

Authors:  M I Bernhard; K A Foon; T N Oeltmann; M E Key; K M Hwang; G C Clarke; W L Christensen; L C Hoyer; M G Hanna; R K Oldham
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

10.  Endothelial-cell proliferation in experimental tumours.

Authors:  J Denekamp; B Hobson
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

View more
  30 in total

1.  Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors.

Authors:  K A Delviks; W S Hu; V K Pathak
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Therapeutic inhibition of angiogenesis.

Authors:  Hua-Tang Zhang; Roy Bicknell
Journal:  Mol Biotechnol       Date:  2003-10       Impact factor: 2.695

3.  [Identification of the molecular bases of metastasis for the development of new therapy strategies of metastatic prostate carcinoma].

Authors:  M Schenck; C Boergermann; F vom Dorp; Y Busch; M Groneberg; B Wilker; S Keitsch; S Moyrer; K W Schmid; M Stuschke; H Ruebben; E Gulbins
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 4.  Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy.

Authors:  G Molema; L F de Leij; D K Meijer
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

Review 5.  The influence of angiogenesis research on management of patients with breast cancer.

Authors:  J Folkman
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

6.  Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

Authors:  H N Lode; T Moehler; R Xiang; A Jonczyk; S D Gillies; D A Cheresh; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy.

Authors:  J G Julias; D Hash; V K Pathak
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.

Authors:  K Riesbeck; A Billström; J Tordsson; T Brodin; K Kristensson; M Dohlsten
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

Review 9.  Oncogenes as inducers of tumor angiogenesis.

Authors:  J Rak; J Filmus; G Finkenzeller; S Grugel; D Marmé; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

Review 10.  Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting.

Authors:  A L Harris; H Zhang; A Moghaddam; S Fox; P Scott; A Pattison; K Gatter; I Stratford; R Bicknell
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.